Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

References

• Simoens S. The Portuguese generic medicines market: a policy analysis. Pharm. Pract.7, 74–80 (2009).
   PubMedGoogle Scholar
• Sermet C, Andrieu V, Godman B et al. Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France. Appl. Health Econ. Health Policy8, 7–24 (2010).
   PubMedGoogle Scholar
• Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden – implications for pharmaceutical companies in Europe. Pharmacoeconomics26, 537–550 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res.8, 357–371 (2008).
   PubMedGoogle Scholar
• Heikkilä R, Mäntyselkä P, Hartikainen-Herranen K, Ahonen R. Customers’ and physicians’ opinions of experiences with generic substitution during the first year in Finland. Health Policy82, 366–374 (2007).
   PubMed Web of Science ®Google Scholar
• Orzella L, Chini F, Rossi P, Borgia P. Physician and patient characteristics associated with prescriptions and cost of drugs in the Lazio region of Italy. Health Policy95, 236–244 (2010).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Persson ME, Wilking N et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv. Res.10, 128 (2010).
   PubMed Web of Science ®Google Scholar
• Garattini L, Motterlini N, Cornago D. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries. Health Policy85, 305–313 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoecon. Outcomes Res.9, 65–83 (2009).
   PubMedGoogle Scholar
• Comma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res.9, 569–581 (2009).
   PubMedGoogle Scholar
• Barry M, Molloy D, Usher C, Tilson L. Drug expenditure in Ireland. Ir. Med. J.101, 299–302 (2008).
   PubMedGoogle Scholar
• Barry M, Usher C, Tilson L. Public drug expenditure in the Republic of Ireland. Expert Rev. Pharmacoecon. Outcomes Res.10, 239–245 (2010).
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Wettermark B et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals3, 2470–2494 (2010).
   Google Scholar
• Simoens S. Generic medicine pricing in Europe: current issues and future perspective. J. Med. Econ.11, 171–175 (2008).
   PubMedGoogle Scholar
• Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for health care systems. Eurohealth14, 18–22 (2008).
   Google Scholar
• Seeley E. Maximizing the benefits from generic competition. Euro Observer10, 8–11 (2008).
   Google Scholar
• Simoens S. Trends in generic prescribing and dispensing in Europe. Exp. Rev. Clin. Pharmacol.1, 497–503 (2008).
   PubMedGoogle Scholar
• Simoens S. International comparison of generic medicine prices. Curr. Med. Res. Opin.23, 2647–2654 (2007).
   PubMed Web of Science ®Google Scholar
• Perry G. The European generic pharmaceutical market in review: 2006 and beyond. J. Gen. Med.4, 4–14 (2006).
   Google Scholar
• McGinn D, Godman B, Lonsdale J et al. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications. Expert Rev. Pharmacoecon. Outcomes Res.10, 73–85 (2010).
   PubMed Web of Science ®Google Scholar
• Duerden M, Hughes D. Generic and therapeutic substitutions in the UK: are they a good thing? Br. J. Clin. Pharmacol.70, 335–341 (2010).
   PubMed Web of Science ®Google Scholar
• Anon. Price falls are following a familiar pattern. Generics Bulletin132, 23 (2010).
   Google Scholar
• Allenet B, Barry H. Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: survey of 1,000 community pharmacists. Pharm. World Sci.25, 197–202 (2003).
   PubMedGoogle Scholar
• Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26, 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Walley T. Drugs, money and society. Br. J. Clin. Pharmacol.70, 342–345 (2010).
   PubMedGoogle Scholar
• Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking – an overview of current approaches and their consequences. Appl. Health Econ. Health Policy7, 1–11 (2009).
   PubMedGoogle Scholar
• Toth F. Healthcare policies over the last 20 years: reforms and counter-reforms. Health Policy95, 82–89 (2010).
   PubMed Web of Science ®Google Scholar
• Brun M, Nobilio L, Ugolini C. Economic incentives in general practice: the impact of pay-for-particupation and pay-for-compliance programs for diabetes care. Health Policy90, 140–148 (2009).
   PubMedGoogle Scholar
• Mason A. New medicines in primary care: a review of influences on general practice prescribing. J. Clin. Pharm. Ther.33, 1–10 (2008).
   PubMedGoogle Scholar
• Sturm H, Austvoll-Dahlgren A, Aaserud M et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst. Rev. (3), CD006731 (2007).
   Google Scholar
• Martens M, Werkhoven M, Severens J, Winkens R. Effects of behaviour independent financial incentive on prescribing behaviour of general practitioners. J. Eval. Clin. Pract.13, 369–373 (2007).
   PubMedGoogle Scholar
• Mason A, Drummond D, Hunter J et al. Prescribing incentive schemes – a useful approach? Appl. Health Econ. Health Policy4, 111–117 (2005).
   PubMedGoogle Scholar
• Butzlaff M, Kempkens D, Schnee M et al. German ambulatory care physicians’ perspective on clinical guidelines – a national survey. BMC Fam. Pract.7, 47 (2006).
   PubMedGoogle Scholar
• Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs – the importance of who says what. Fam. Pract.20, 61–68 (2003).
   PubMed Web of Science ®Google Scholar
• Denig P, Witterman C, Schouten H. Scope and nature of prescribing decisions made by general practioners. Qual. Saf. Health Care11, 137–143 (2002).
   PubMedGoogle Scholar
• Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet362, 1225–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Prosser H, Walley T. A qualitative study of GPs’ and PCO stakeholders’ views on the importance and influence of cost on prescribing. Soc. Sci. Med.60, 1335–1346 (2005).
   PubMed Web of Science ®Google Scholar
• Pegler C, Underhill J. Evaluating promotional material from industry: an evidence-based approach. Pharmaceutical J.274, 271–274 (2005).
   Google Scholar
• Ferner R, Lenney W, Marriott J. Controversy over generic substitution. Br. Med. J.340, c2548 (2010).
   PubMed Web of Science ®Google Scholar
• Valles J-A, Barreiro M, Cereza G et al. A prospective multicentre study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy65, 269–275 (2003).
   PubMedGoogle Scholar
• Shrank W, Cox E, Fischer M, Mehta J, Choudry N. Patients’ perception of generic medications. Health Affairs28, 546–556 (2009).
   PubMed Web of Science ®Google Scholar
• Kjoenniksen I, Lindbaek M, Grannas A. Patients’ attitudes towards and experiences of generic drug substitution in Norway. Pharm. World Sci.28, 284–289 (2006).
   PubMed Web of Science ®Google Scholar
• Sagardui-Villamor JK, Lacalle Rodriquez-Labajo M, Casado-Buendia S. [Substitution of generic for brand medicines in primary care. Factors associated to effuse change]. Aten Primaria36, 498–493 (2005)
   Google Scholar
• Andersson K, Jorgensem T, Carlsten A. Physicians’ opinions and experiences of the pharmaceutical benefits reform. Scand. J. Public Health34, 654–659 (2006).
   PubMed Web of Science ®Google Scholar
• Garattini S, Bertele V, Godman B et al. Enhancing the rational use of new medicines across European healthcare systems – a position paper. Eur. J. Clin. Pharmacol.64, 1137–1138 (2008).
   PubMed Web of Science ®Google Scholar
• Walker A, Booth C, Brown A, Paterson K. How much good do new medicines do? Basic Clin. Pharm. Toxicol.105(Suppl. 1), 29 (2009).
   Google Scholar
• Wettermark B, Godman B, Eriksson C et al. [Introduction of new medicines into European healthcare systems]. GGW10(3), 24–34 (2010).
   Google Scholar
• Luijn J, Gribnau F, Leufkens H. Superior efficacy of new medicines? Eur. J. Clin. Pharmacol.66, 445–448 (2010).
   PubMedGoogle Scholar
• Lee T, Emanuel E. Tier 4 drugs and the fraying of the social compact. N. Engl. J. Med.359, 333–335 (2008).
   PubMed Web of Science ®Google Scholar
• Ostoni R, Hegney D, Jackson C et al. Systematic review of interventions to improve prescribing. Ann. Pharmacother.43, 502–513 (2009).
   PubMedGoogle Scholar
• Grimshaw J, Thomas R, MacLennan G et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol. Assess.8(6), iii–iv, 1–72 (2004).
   Web of Science ®Google Scholar
• Grimshaw J, Campbell M, Eccles M et al. Experimental and quasi-experimental designs for evaluating guidelines implementation strategies. Fam. Pract.17, S11–S16 (2000).
   PubMed Web of Science ®Google Scholar
• Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics27, 1–4 (2009).
   PubMed Web of Science ®Google Scholar
• Lindgren P, Graff J, Olson A et al. Cost-effectiveness of high-dose atorvastatin compared with regular simvastatin. Eur. Heart J.28, 1448–1453 (2007).
   PubMed Web of Science ®Google Scholar
• Studies in Drug Utilization – Methods and Applications. Bergman U, Gimsson A, Wahba A, Westerholm B (Eds). WHO Regional Publications, Copenhagen, Denmark (1979).
   Google Scholar
• World Health Organization (WHO). The selection of essential drugs. World Health Organ. Tech. Rep. Ser. No. 615 (1977).
   Google Scholar
• Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – are drug utilisation data comparable? Eur. J. Clin. Pharmacol.56, 723–727 (2000).
   PubMed Web of Science ®Google Scholar
• Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoecon. Outcomes Res.9, 475–484 (2009).
   PubMedGoogle Scholar
• Walley T, Folino-Gallo P, Schwabe U, Van Ganse E. Variations and increase in use of statins across Europe: data from administrative databases. Br. Med. J.328, 385–386 (2004).
   PubMed Web of Science ®Google Scholar
• Vlahović-Palcevski V, Gantumur M, Radoševic N et al. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm. World Sci.32, 125–129 (2010).
   PubMedGoogle Scholar
• Wettermark B, Pehrsson A, Juhasz-Haverinen M et al. Financial incentives linked to self-assessment of prescribing patterns – a new approach for quality improvement of drug prescribing in primary care. Qual. Prim. Care17, 179–189 (2009).
   PubMedGoogle Scholar
• Wettermark B, Godman B, Neovius M et al. Initial effects of a reimbursement restriction to improve the cost–effectiveness of antihypertensive treatment. Health Policy94, 221–229 (2010).
   PubMed Web of Science ®Google Scholar
• Bero L, Grilli R, Grimshaw J et al. Getting research into practice. Br. Med. J.317, 465–468 (1998).
   PubMed Web of Science ®Google Scholar
• Barton S. Using clinical evidence. Br. Med. J.322, 503–504 (2001).
   PubMed Web of Science ®Google Scholar
• Walley T, Folin-Galo P, Stephens P, Van Ganse E. Trends in prescribing and utilisation of statins and other lipid lowering drugs across Europe 1997–2003. Br. J. Clin. Pharmacol.60, 543–551 (2005).
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 with diabetes: a randomised placebo-controlled trial. Lancet361, 2005–2016 (2003).
   PubMed Web of Science ®Google Scholar
• Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association for the Study of Diabetes. Eur. Heart J.28, 88–136 (2007).
   PubMed Web of Science ®Google Scholar
• Josan K, Majumdar S, McAlister F. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ178, 576–584 (2008).
   PubMed Web of Science ®Google Scholar
• Walley T, Folino-Gallo P, Schwabe U, Van Ganse E, Stephens P. Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe. Eur. J. Clin. Pharmacol.60, 503–511 (2004).
   PubMed Web of Science ®Google Scholar